



Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities

For the month ended: 30 September 2022

Status: New Submission

To : Hong Kong Exchanges and Clearing Limited

Name of Issuer: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Date Submitted: 07 October 2022

I. Movements in Authorised / Registered Share Capital

1. Type of shares	Ordinary shares	Class of shares	Class H	Listed on SEHK (Note 1)	Yes	
Stock code	02315	Description				
	Number of authorised/registered shares	Par value		Authorised/registered share capital		
Balance at close of preceding month	108,071,920	RMB	1	RMB	108,071,920	
Increase / decrease (-)	2,710,000			RMB	2,710,000	
Balance at close of the month	110,781,920	RMB	1	RMB	110,781,920	

2. Type of shares	Ordinary shares	Class of shares	Other class (specify in description)	Listed on SEHK (Note 1)	No	
Stock code	-	Description	Unlisted Shares			
	Number of authorised/registered shares	Par value		Authorised/registered share capital		
Balance at close of preceding month	288,616,500	RMB	1	RMB	288,616,500	
Increase / decrease (-)	0			RMB	0	
Balance at close of the month	288,616,500	RMB	1	RMB	288,616,500	

Total authorised/registered share capital at the end of the month: RMB 399,398,420

Remarks:

The H shares of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. were newly listed on the Main Board of The Stock Exchange of Hong Kong Limited on 1 September 2022. The information contained in section I under "Balance at close of preceding month" refers to the "Balance upon listing on 1 September 2022".

II. Movements in Issued Shares

1. Type of shares	Ordinary shares	Class of shares	Class H	Listed on SEHK (Note 1)	Yes	
Stock code	02315	Description				
Balance at close of preceding month		108,071,920				
Increase / decrease (-)		2,710,000				
Balance at close of the month		110,781,920				

2. Type of shares	Ordinary shares	Class of shares	Other class (specify in description)	Listed on SEHK (Note 1)	No	
Stock code	-	Description	Unlisted Shares			
Balance at close of preceding month		288,616,500				
Increase / decrease (-)		0				
Balance at close of the month		288,616,500				

Remarks:

The H shares of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. were newly listed on the Main Board of The Stock Exchange of Hong Kong Limited on 1 September 2022. The information contained in section II under "Balance at close of preceding month" refers to the "Balance upon listing on 1 September 2022".

III. Details of Movements in Issued Shares**(A). Share Options (under Share Option Schemes of the Issuer)** Not applicable**(B). Warrants to Issue Shares of the Issuer which are to be Listed** Not applicable**(C). Convertibles (i.e. Convertible into Issue Shares of the Issuer which are to be Listed)** Not applicable**(D). Any other Agreements or Arrangements to Issue Shares of the Issuer which are to be listed, including Options (other than Share Options Schemes)** Not applicable**(E). Other Movements in Issued Share**

1. Type of shares issuable (Note 5 and 6)	Ordinary shares	Class of shares	Class H	Shares issuable to be listed on SEHK (Note 1, 5 and 6)	Yes	
Stock code of shares issuable (if listed on SEHK) (Note 1, 5 and 6)	02315					
Type of Issue	At price (if applicable)		Issue and allotment date (Note 5 and 6)	General Meeting approval date (if applicable)	No. of new shares of issuer issued during the month pursuant thereto (E)	No. of new shares of issuer which may be issued pursuant thereto as at close of the month
	Currency	Amount				
1). Other (Please specify) Issue of H Shares pursuant to the partial exercise of the Over-allotment Option	HKD	25.22	28 September 2022		2,710,000	0

Total E (Ordinary shares Class H): 2,710,000Total increase / decrease (-) in Ordinary shares Class H during the month (i.e. Total of A to E) 2,710,000

IV. Information about Hong Kong Depositary Receipt (HDR) Not applicable

V. Confirmations

Not applicable

Submitted by: Wang Yongliang

Title: Joint Company Secretary

(Director, Secretary or other Duly Authorised Officer)

Notes

1. SEHK refers to Stock Exchange of Hong Kong.
2. Items (i) to (viii) are suggested forms of confirmation which may be amended to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, no further confirmation is required to be made in this return.
3. "Identical" means in this context:
 - . the securities are of the same nominal value with the same amount called up or paid up;
 - . they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
 - . they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
4. If there is insufficient space, please submit additional document.
5. In the context of repurchase of shares:
 - . "shares issuable to be listed on SEHK" should be construed as "shares repurchased listed on SEHK"; and
 - . "stock code of shares issuable (if listed on SEHK)" should be construed as "stock code of shares repurchased (if listed on SEHK)"; and
 - . "type of shares issuable" should be construed as "type of shares repurchased"; and
 - . "issue and allotment date" should be construed as "cancellation date"
6. In the context of redemption of shares:
 - . "shares issuable to be listed on SEHK" should be construed as "shares redeemed listed on SEHK"; and

- . “stock code of shares issuable (if listed on SEHK)” should be construed as “stock code of shares redeemed (if listed on SEHK)”; and
- . “type of shares issuable” should be construed as “type of shares redeemed”; and
- . “issue and allotment date” should be construed as “redemption date”